Bivalent swine influenza virus vaccine

1. A bivalent immunogenic composition comprising: a) a modified live H3N2 virus of swine influenza, and b) a modified live H1N1 virus of swine influenza, wherein the modified live H3 and H1 viruses of swine influenza are attenuated and encode a carboxy-terminal truncated NS1 protein comprising NS1 amino acids 1 through 124, 1 through 125, 1 through 126, 1 through 127 or 1 through 128, wherein the amino terminal amino acid is number 1, comprising:

a. the modified live H3N2 virus of swine influenza wherein the modified live H3 virus of swine influenza is TX/98/del 126 containing the HA, NA, PB2, PB1, PA, NP, and M from A/Swine/Texas/4199-2/98 and the NS1-126 gene is from A/Swine/Texas/4199-2/98 and wherein the NA and HA gene segments further comprise:

i. a nucleic acid sequence of gene segments encoding NA and HA proteins having an amino acid sequence with at least 98% identity to the amino acid sequence as set forth in SEQ ID NO:3 or SEQ ID NO:4; or

ii. a NA and HA protein having an amino acid sequence with at least 98% identity to the amino acid sequence as set forth in SEQ ID NO:3 or SEQ ID NO:4; and

b. the modified live H1N1 virus of swine influenza wherein the modified live H1 virus of swine influenza contains HA and NA from A/swine/Minnesota/37866/1999 (H1N1) and PB2, PB1, PA, NP, M from A/Swine/Texas/4199-2/98 (H3N2) and the NS1-126 gene is from A/Swine/Texas/4199-2/98 (H3N2) and wherein the NA and HA gene segments further comprise:

i. a nucleic sequence encoding NA and HA proteins having an amino acid sequence with greater than 98% identity to the amino acid sequence as set forth in SEQ ID NO:7 or SEQ ID NO:8; or

ii. a NA and HA protein having an amino acid sequence with greater than 98% identity to the amino acid sequence as set forth in SEQ ID NO:7 or SEQ ID NO:8,

wherein the bivalent immunogenic composition improves at least one efficacy parameter selected from the group consisting of: a reduction in weight loss, a lower virus load, a reduction in lung lesions, a reduced shedding, a reduced rectal temperature, or combinations thereof, in comparison to a subject of the same species immunized with a monovalent modified live H3 or H1 influenza virus alone.

2. The bivalent immunogenic composition of claim 1 , wherein the modified live H3 virus of swine influenza is TX/98/del 126 containing the HA, NA, PB2, PB1, PA, NP, and M from A/Swine/Texas/4199-2/98 and the NS1-126 gene is from A/Swine/Texas/4199-2/98 and, wherein the modified live H1 virus of swine influenza contains HA and NA from A/swine/Minnesota/37866/1999 (H1N1) and PB2, PB1, PA, NP, M from A/Swine/Texas/4199-2/98 (H3N2) and the NS1-126 gene is from A/Swine/Texas/4199-2/98 (H3N2).

3. The bivalent immunogenic composition of claim 1 , wherein the modified live H3 and H1 viruses of swine influenza act synergistically together.

4. The bivalent immunogenic composition of claim 1 , wherein the concentration of the modified live H3 and H1 viruses of swine influenza are reduced compared to the concentration of the H3 virus of swine influenza in a monovalent immunogenic composition and the concentration of the H1 virus of swine influenza in a monovalent immunogenic composition.

5. The bivalent immunogenic composition of claim 1 , wherein the modified live H3 virus of swine influenza increases the protection against a heterologous challenge, a H1 challenge and/or a H1N1 challenge.

6. A method for immunizing a subject comprising administering to such subject an immunogenic composition of claim 1 .

7. A method of treating or preventing clinical signs caused by swine influenza virus in a subject of need, the method comprising administering to the subject a therapeutically effective amount of an immunogenic composition according to claim 1 .

8. A method of reducing the viral shedding in a subject of need, in comparison to a subject of a non-immunized control group of the same species, the method comprising administering to the subject a therapeutically effective amount of an immunogenic composition according to claim 1 .

9. A method of reducing the viral shedding in a subject of need, in comparison to a subject of an immunized control group of the same species immunized with a monovalent modified live H3 or H1 virus of swine influenza, the method comprising administering to the subject a therapeutically effective amount of an immunogenic composition according to claim 1 .

10. A method of vaccinating a subject having anti-SIV antibodies comprising the step of administering to said animal a single effective dose of an immunogenic composition according to claim 1 .

11. A method for preventing or reducing early SIV infections in a subject, the method comprising administering to the subject a therapeutically effective amount of an immunogenic composition according to claim 1 .

12. The method of claim 6 , wherein said subject is selected from the list consisting of swine, cattle, cat and dog.

13. The method of claim 6 , wherein the immunogenic composition is administered once.

14. The method of any claim 6 , wherein said immunogenic composition is administered intranasal.

15. The method of claim 6 , wherein said immunogenic composition is administered to sows during pregnancy and lactation.

16. The method of claim 6 , wherein the immunogenic composition is administered to pigs within the first month of age, within the first two weeks of age or within the first week of age.

17. The method of claim 6 , wherein the subject is Swine influenza virus maternal antibody positive.

18. The method of claim 6 , wherein the immunogenic composition comprises 2 to 8 log 10 of the modified live H1 virus of swine influenza and/or 2 to 8 log 10 of the modified live H3 virus of swine influenza.

19. The method of claim 6 , wherein said method results in an improvement in an efficacy parameter selected from the group consisting of: a reduction in weight loss, a lower virus load, a reduction in lung lesions, a reduced shedding, a reduced rectal temperature, or combinations thereof, in comparison to a subject of a non-immunized control group of the same species.

20. The method of claim 6 , wherein said method results in an improvement in an efficacy parameter selected from the group consisting of: a reduction in weight loss, a lower virus load, a reduction in lung lesions, a reduced shedding, a reduced rectal temperature, or combinations thereof, in comparison to a subject of the same species immunized with a monovalent modified live H3 or H1 influenza virus.

21. The method of claim 6 , wherein the treatment or prophylaxis results in shortening of the virus load phase as compared to animals of a non-treated control group of the same species.

22. The method of claim 6 , wherein the treatment or prophylaxis results in a reduction of the shedding from day 2 after challenge or infection.

23. The method of claim 6 , wherein the subject is immunized with a lower concentration of the immunogenic composition of claim 1 compared to a subject of the same species immunized with a monovalent modified live H3 or H1 influenza virus.

24. The method of claim 6 , wherein the modified live H3 and H1 viruses of swine influenza act synergistically together.

25. The method of claim 6 , wherein the concentration of the modified live H3 and H1 viruses of swine influenza are reduced compared to the concentration of the H3 virus of swine influenza in a monovalent immunogenic composition and the concentration of the H1 virus of swine influenza in a monovalent immunogenic composition.

26. The method of claim 6 , wherein the modified live H3 virus of swine influenza increases the protection against a heterologous challenge, a H1 challenge and/or a H1N1 challenge.

27. A bivalent immunogenic composition comprising: a) a modified live H3N2 virus of swine influenza, and b) a modified live H1N1 virus of swine influenza, wherein the modified live H3N1 and H1N1 viruses of swine influenza are attenuated and encode a carboxy-terminal truncated NS1 protein comprising NS1 amino acids 1 through 126, wherein the amino terminal amino acid is number 1 wherein,

a. the modified live H3N2 virus of swine influenza contains the HA, NA, PB2, PB1, PA, NP, and M from A/Swine/Texas/4199-2/98 and the NS1-126 gene is from A/Swine/Texas/4199-2/98 and wherein the NA and HA gene segments further comprise:

i. a nucleic acid sequence of gene segments encoding NA and HA proteins having an amino acid sequence with at least 98% identity to the amino acid sequence as set forth in SEQ ID NO:3 or SEQ ID NO:4; or

ii. a NA and HA protein having an amino acid sequence with at least 98% identity to the amino acid sequence as set forth in SEQ ID NO:3 or SEQ ID NO:4; and

b. the modified live H1N1 virus of swine influenza contains HA and NA from A/swine/Minnesota/37866/1999 (H1N1) and PB2, PB1, PA, NP, M from A/Swine/Texas/4199-2/98 (H3N2) and the NS1-126 gene is from A/Swine/Texas/4199-2/98 (H3N2) and wherein the NA and HA gene segments further comprise:

i. a nucleic sequence encoding NA and HA proteins having an amino acid sequence with greater than 98% identity to the amino acid sequence as set forth in SEQ ID NO:7 or SEQ ID NO:8; or

ii. a NA and HA protein having an amino acid sequence with greater than 98% identity to the amino acid sequence as set forth in SEQ ID NO:7 or SEQ ID NO:8,

wherein the bivalent immunogenic composition improves at least one efficacy parameter selected from the group consisting of: a reduction in weight loss, a lower virus load, a reduction in lung lesions, a reduced shedding, a reduced rectal temperature, or combinations thereof, in comparison to a subject of the same species immunized with a monovalent modified live H3N1 or H1N1 influenza virus alone.

28. A bivalent immunogenic composition comprising: a) a modified live H3N2 virus of swine influenza, and b) a modified live H1N1 virus of swine influenza, wherein the modified live H3N1 and H1N1 viruses of swine influenza are attenuated and encode a carboxy-terminal truncated NS1 protein comprising NS1 amino acids 1 through 124, 1 through 125, 1 through 126, 1 through 127 or 1 through 128, wherein the amino terminal amino acid is number 1 wherein,

a. the modified live H3N2 virus of swine influenza contains the HA, NA, PB2, PB1, PA, NP, and M from A/Swine/Texas/4199-2/98 and the NS1gene is from A/Swine/Texas/4199-2/98 and wherein the NA and HA gene segments further comprise:

i. a nucleic acid sequence of gene segments encoding NA and HA proteins having an amino acid sequence with at least 98% identity to the amino acid sequence as set forth in SEQ ID NO:3 or SEQ ID NO:4; or

ii. a NA and HA protein having an amino acid sequence with at least 98% identity to the amino acid sequence as set forth in SEQ ID NO:3 or SEQ ID NO:4; and

b. the modified live H1N1 virus of swine influenza contains HA and NA from A/swine/Minnesota/37866/1999 (H1N1) and PB2, PB1, PA, NP, M from A/Swine/Texas/4199-2/98 (H3N2) and the NS1gene is from A/Swine/Texas/4199-2/98 (H3N2) and wherein the NA and HA gene segments further comprise:

i. a nucleic sequence encoding NA and HA proteins having an amino acid sequence with greater than 98% identity to the amino acid sequence as set forth in SEQ ID NO:7 or SEQ ID NO:8; or

ii. a NA and HA protein having an amino acid sequence with greater than 98% identity to the amino acid sequence as set forth in SEQ ID NO:7 or SEQ ID NO:8, wherein the bivalent immunogenic composition improves at least one efficacy parameter selected from the group consisting of: a reduction in weight loss, a lower virus load, a reduction in lung lesions, a reduced shedding, a reduced rectal temperature, or combinations thereof, in comparison to a subject of the same species immunized with a monovalent modified live H3N1 or H1N1 influenza virus alone.